IPO registrations (S-1, F-1) · Registrants
Arcellx, Inc.
- SEC CIK
- 1786205 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2022-01-14, last 2022-06-15; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2022-02-07; declared effective 2022-02-03
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 800 BRIDGE PARKWAY, Redwood City, CA 94065
- EIN
- 47-2855917
- EDGAR entity type
- operating
- Insiders and CEO pay
- Arcellx, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2022-01-31)
- Final price
- $15.00 per share, within the range (424B4 filed 2022-02-07, an initial public offering)
- Shares sold
- 8,250,000
- Gross proceeds
- $123,750,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ACLX
- Lead underwriters
- BofA Securities; Leerink Partners; Barclays; William Blair
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ARCELLX, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: ARCELLX, INC. EXACT (EIN (EXACT))
- Form D issuer: Arcellx, Inc. EXACT (CIK (EXACT))
- SEC filer: Arcellx, Inc. EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2022-01-14 | S-1 | S-1 (registration) | Arcellx, Inc. | 0001193125-22-010026 ↗ |
| 2022-01-31 | S-1/A | S-1/A (amendment) | Arcellx, Inc. | 0001193125-22-022267 ↗ |
| 2022-02-03 | EFFECT | EFFECT (declared effective) | Arcellx, Inc. | 9999999995-22-000328 ↗ |
| 2022-02-07 | 424B4 | 424B4 (final prospectus) | Arcellx, Inc. | 0001193125-22-029768 ↗ |
| 2022-06-14 | S-1 | S-1 (registration) | Arcellx, Inc. | 0001193125-22-173436 ↗ |
| 2022-06-14 | S-1/A | S-1/A (amendment) | Arcellx, Inc. | 0001193125-22-173887 ↗ |
| 2022-06-15 | S-1/A | S-1/A (amendment) | Arcellx, Inc. | 0001193125-22-174521 ↗ |
| 2022-06-15 | S-1MEF | S-1MEF (added securities) | Arcellx, Inc. | 0001193125-22-175013 ↗ |
| 2022-06-15 | EFFECT | EFFECT (declared effective) | Arcellx, Inc. | 9999999995-22-001836 ↗ |
| 2022-06-16 | 424B4 | 424B4 (final prospectus) | Arcellx, Inc. | 0001193125-22-175611 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-31 | S-1/A | registration statement | $15.00–$17.00 | 8,250,000 | - | Nasdaq ACLX | 4 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 4 | document ↗ | |
| 2022-02-07 | 424B4 | final prospectus | $15.00 | 8,250,000 | $123,750,000 | Nasdaq ACLX | 4 | primary document; price sentence, shares sentence, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BASKETT FOREST | TenPercentOwner | 4 | 2022 | ||
| Behbahani Ali | Director | 8 | 2022–2026 | ||
| Carroll Jill | Director | 10 | 2022–2026 | ||
| Elghandour Rami | Director,Officer | See Remarks; SEE REMARKS | 24 | 2022–2026 | |
| Florence Anthony A. Jr. | TenPercentOwner | 4 | 2022 | ||
| George Simeon | TenPercentOwner | 3 | 2022–2023 | ||
| Heery Christopher | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 47 | 2022–2026 | |
| Lubner David Charles | Director | 8 | 2022–2026 | ||
| Makhzoumi Mohamad | TenPercentOwner | 4 | 2022 | ||
| NEA 15 GP, LLC | TenPercentOwner | 4 | 2022 | ||
| NEA Partners 15, L.P. | TenPercentOwner | 4 | 2022 | ||
| New Enterprise Associates 15, L.P. | TenPercentOwner | 4 | 2022 | ||
| Novo Holdings A/S | TenPercentOwner | 2 | 2022 | ||
| Patel Kavita | Director | 25 | 2022–2026 | ||
| SANDELL SCOTT D | TenPercentOwner | 5 | 2022 | ||
| Sonsini Peter W. | TenPercentOwner | 4 | 2022 | ||
| SR One Capital Fund I Aggregator LP | TenPercentOwner | 3 | 2022–2023 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | TenPercentOwner | 3 | 2022–2023 | ||
| SR ONE CAPITAL PARTNERS I, LP | TenPercentOwner | 3 | 2022–2023 | ||
| SR One Co-Invest II, LLC | TenPercentOwner | 3 | 2022–2023 | ||
| THIBAULT LANCE E | Officer | See Remarks | 1 | 2022 | |
| Williams Lewis T | Director | 2 | 2022 | ||
| Yoon Derek | Director | 3 | 2022–2024 | ||
| SR One Co-Invest II Manager, LLC | TenPercentOwner | 2 | 2022–2023 | ||
| Ware Olivia C | Director | 8 | 2022–2026 | ||
| Gilson Michelle | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 26 | 2022–2026 | |
| GILEAD SCIENCES, INC. | TenPercentOwner | 1 | 2023 | ||
| Galligan Andrew H | Director | 4 | 2025–2026 | ||
| Myers Kristin | Director | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-02-06 | Arcellx, Inc. | Biotechnology | $100,000,003 | $100,000,003 | 1 | 1 |
| 2022-03-10 | Arcellx, Inc. | Biotechnology | $9,999,986 | $9,999,986 | 1 | 1 |
| 2021-04-09 | Arcellx, Inc. | Biotechnology | $120,000,023 | $120,000,023 | 32 | 2 |
| 2019-08-22 | Arcellx, Inc. | Biotechnology | $83,681,224 | $42,840,613 | 18 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | ARCELLX, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Arcellx, Inc. | MD | Form D private offerings | CIK (EXACT) |
| SEC filer | Arcellx, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | ARCELLX, INC. | State business registries | name and state | |
| Form 5500 plan sponsor | ARCELLX, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), CA first:
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
- COLLATERAL THERAPEUTICS INC CA
- Life Technologies Corp CA
- DRUGABUSE SCIENCES INC CA
- STRATAGENE CORP CA
- Cordex Pharma, Inc. CA
- COTHERIX INC CA
- Cardiff Oncology, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health